Study guide

10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis

Key Takeaways Explain This Topic AI

Rheumatoid Arthritis (RA) is an autoimmune systemic inflammatory disorder causing symmetric, destructive polyarthritis targeting small joints (MCP, PIP, MTP, wrists) with prolonged morning stiffness (>60 minutes); anti-cyclic citrullinated peptide (anti-CCP) antibodies provide >95% specificity and predict erosive disease.

Early initiation of disease-modifying antirheumatic drugs (DMARDs) within 3 months of RA diagnosis prevents irreversible joint destruction; Methotrexate is the gold-standard anchor csDMARD requiring folic acid supplementation (1 mg/day) and routine monitoring of CBC, liver enzymes, and renal function.

Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease diagnosed via the 2019 EULAR/ACR criteria requiring positive ANA (≥1:80) followed by weighted criteria; Hydroxychloroquine is the foundational life-prolonging therapy for all SLE patients, requiring baseline and annual retinal toxicity screening after 5 years.

Polymyalgia Rheumatica (PMR) presents in adults ≥50 with acute/subacute bilateral aching and morning stiffness in the shoulder and pelvic girdles, markedly elevated ESR/CRP, and normal muscle enzymes (CK); it exhibits a dramatic clinical response within 24–72 hours to low-dose prednisone (15–20 mg/day).

Giant Cell Arteritis (GCA) is a large-vessel vasculitis that represents an ophthalmic emergency; if temporal headache, jaw claudication, scalp tenderness, or visual symptoms occur, high-dose systemic corticosteroids (prednisone 40–60 mg/day or IV pulse methylprednisolone) must be initiated IMMEDIATELY without waiting for temporal artery biopsy results.

Last updated: August 2026

Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis

Autoimmune rheumatologic conditions represent complex, multisystem disorders driven by loss of immunological self-tolerance, chronic autoantibody production, and uncontrolled cytokine cascades. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) , early disease detection, accurate serologic interpretation, aggressive initiation of disease-modifying therapies, and proactive surveillance for medication toxicity and life-threatening vascular complications are paramount board competencies.

  • 1. Rheumatoid Arthritis (RA)
  • Pathophysiology & Immunopathogenesis

Rheumatoid arthritis is a chronic, systemic autoimmune inflammatory disease characterized by destructive synovitis. Genetic susceptibility (specifically the HLA-DRB1 "shared epitope" ) interacts with environmental triggers (such as tobacco smoking and periodontal disease) to stimulate the enzymatic conversion of arginine to citrulline ( citrullination ). +---------------------------------------------------------------------------------------------------+

  • | RHEUMATOID ARTHRITIS IMMUNOPATHOGENESIS |
  • | |
  • | Environmental Trigger (Smoking) + Genetic Susceptibility (HLA-DRB1 Shared Epitope) |
  • | | |
  • | v |
  • | Post-Translational Protein Citrullination -> Anti-CCP & RF Autoantibody Production |
  • | | |
  • | v |
  • | Synovial Microvascular Proliferation & Massive Infiltration (T cells, B cells, Macrophages) |
  • | | |
  • | v |
  • | Cytokine Hypersecretion (TNF-alpha, IL-1, IL-6, IL-17, RANKL) |
  • | | |
  • | v |
  • | INVASIVE SYNOVIAL PANNUS FORMATION (Hyperplastic synoviocytes + Osteoclasts + Chondrocytes) |
  • | | |
  • | v |
  • | Marginal Bone Erosions + Cartilage Degradation + Tendon Rupture + Systemic Vascular Inflammation|
  • +---------------------------------------------------------------------------------------------------+
  • Clinical Presentation & Deformity Patterns

Joint Manifestations:

Symmetric, polyarticular inflammatory arthritis affecting small joints of the hands and feet.

Primary Targets: Metacarpophalangeal (MCP) joints, Proximal Interphalangeal (PIP) joints, Wrists, Metatarsophalangeal (MTP) joints, Knees, Ankles, and Cervical Spine (specifically C1-C2 atlantoaxial articulation).

Characteristic Spares: RA characteristically SPARES the Distal Interphalangeal (DIP) joints and the thoracolumbar spine.

Symptom Chronometry: Prolonged morning stiffness lasting > 60 minutes >60\text{ minutes} > 60 minutes (often 2–3 hours), which characteristically improves with physical movement, warm showers, and gentle exercise throughout the day.

Advanced Joint Deformities:

Swan-Neck Deformity: Hyperextension of PIP joint with compensatory flexion of DIP joint.

Boutonnière Deformity: Flexion of PIP joint with hyperextension of DIP joint (rupture of central extensor tendon slip).

Ulnar Drift (Deviation): Subluxation and lateral deviation of the fingers at the MCP joints.

Z-Deformity of the Thumb: Fixed flexion at MCP joint and hyperextension at IP joint.

Rheumatoid Nodules: Firm, non-tender, subcutaneous nodules located over pressure points (olecranon bursa, extensor forearm, Achilles tendon, and pulmonary parenchyma). +---------------------------------------------------------------------------------------------------+

  • | EXTRA-ARTICULAR MANIFESTATIONS OF RHEUMATOID ARTHRITIS |
  • | |
  • | ORGAN SYSTEM CLINICAL MANIFESTATION & PATHOLOGY |
  • | --------------------------------------------------------------------------------------------- |
  • | Ocular Keratoconjunctivitis sicca (Secondary Sjögren syndrome, 15-20%), Episcleritis,|
  • | Scleritis (deep agonizing eye pain, risk of globe perforation: scleromalacia)|
  • | Pulmonary Rheumatoid Interstitial Lung Disease (ILD - UIP/NSIP patterns), Pleural |
  • | effusions (exudative with characteristic VERY LOW GLUCOSE < 30 mg/dL), |
  • | Caplan syndrome (RA + pneumoconiosis + pulmonary nodules) |
  • | Cardiovascular Accelerated Atherosclerosis (leading cause of mortality in RA!), Pericarditis|
  • | Hematologic Anemia of Chronic Disease (normocytic/microcytic), Thrombocytosis (acute |
  • | phase marker), FELTY SYNDROME (Triad: Severe RA + Splenomegaly + Neutropenia)|
  • | Neurologic Cervical Spine Atlantoaxial Subluxation (C1-C2 instability with danger of |
  • | quadriplegia/death during intubation!), Peripheral entrapment neuropathies |
  • | Vascular Rheumatoid Vasculitis (palpable purpura, cutaneous ulcerations, mononeuritis)|
  • +---------------------------------------------------------------------------------------------------+

Diagnostic Serology, Synovial Fluid & Radiography +---------------------------------------------------------------------------------------------------+

  • | DIAGNOSTIC SEROLOGY COMPARISON IN RA |
  • | |
  • | SEROLOGIC MARKER SENSITIVITY SPECIFICITY CLINICAL SIGNIFICANCE |
  • | --------------------------------------------------------------------------------------------- |
  • | Anti-CCP (ACPA) ~ 70 - 80% > 95 - 98% Highest specificity; appears years |
  • | (Anti-Cyclic Citrullinated before clinical onset; strong |
  • | Peptide Antibody) predictor of aggressive erosive RA. |
  • | |
  • | Rheumatoid Factor (RF) ~ 70 - 80% ~ 75 - 80% IgM antibody directed against Fc |
  • | (IgM against IgG Fc) portion of IgG. Also positive in: |
  • | Sjögren, SLE, Hepatitis C, TB, |
  • | Infective Endocarditis, Healthy aged. |
  • | |
  • | ESR & CRP ~ 80 - 90% Non-specific Correlates with active synovitis and |
  • | systemic disease activity. |
  • +---------------------------------------------------------------------------------------------------+

Synovial Fluid Analysis: Inflammatory profile: yellow/turbid fluid, leukocyte count 2 , 000 – 50 , 000 / μ L 2,000\text{--}50,000/\mu\text{L} 2 , 000 – 50 , 000/ μ L with > 50 % >50\% > 50% polymorphonuclear leukocytes (PMNs), normal glucose-to-serum ratio, negative Gram stain, and no crystals.

Plain Radiography: Early findings reveal periarticular soft tissue swelling and periarticular osteopenia (demineralization) ; progressive disease demonstrates marginal bone erosions (at the joint capsule insertions where bone lacks protective cartilage) and uniform, symmetric joint space narrowing.

Pre-Operative Cervical Spine Mandate: Any patient with longstanding RA undergoing elective surgery requiring general endotracheal intubation MUST obtain flexion and extension cervical spine radiographs to rule out occult atlantoaxial subluxation (anterior atlantodental interval > 3 mm >3\text{ mm} > 3 mm ) to prevent spinal cord transection during airway manipulation.

Stepwise Guideline-Directed Pharmacotherapy (ACR Guidelines)

Treat-to-Target (T2T) strategy aims for clinical remission or low disease activity. Disease-Modifying Antirheumatic Drugs (DMARDs) must be initiated immediately upon diagnosis (ideally within 3 months of symptom onset): +---------------------------------------------------------------------------------------------------+

  • | STEPWISE PHARMACOTHERAPY ALGORITHM FOR RA |
  • | |
  • | FIRST-LINE: CONVENTIONAL SYNTHETIC DMARD (csDMARD) |
  • | * METHOTREXATE (MTX) is the foundational anchor drug of choice (15-25 mg PO or SubQ ONCE WEEKLY)|
  • | - Mechanism: Dihydrofolate reductase inhibitor; increases adenosine anti-inflammatory actions.|
  • | - Mandatory Co-Prescription: FOLIC ACID 1 mg daily (reduces stomatitis, GI upset, cytopenias).|
  • | - Monitoring: Baseline & every 8-12 weeks: CBC (myelosuppression), LFTs (hepatotoxicity), |
  • | Serum Creatinine (renally excreted; dose reduce/avoid if eGFR < 30 mL/min). |
  • | - Absolute Contraindications: PREGNANCY (Teratogenic / Category X), severe hepatic cirrhosis, |
  • | active heavy alcohol consumption, severe renal impairment. |
  • | - Toxicity Red Flag: Acute dry cough, fever, dyspnea -> Methotrexate-Induced Pneumonitis. |
  • | * Alternative / Combination csDMARDs: |
  • | - Hydroxychloroquine (HCQ) 200-400 mg daily (mild disease; annual eye exams for retinopathy). |
  • | - Sulfasalazine 1-3 g daily (screen G6PD; causes orange discoloration of urine/tears). |
  • | - Leflunomide (pyrimidine synthesis inhibitor; long half-life, requires cholestyramine washout)|
  • | | |
  • | v (Moderate-to-High disease activity despite 3 months csDMARD)|
  • | SECOND-LINE: BIOLOGIC DMARDs (bDMARDs) OR TARGETED SYNTHETIC DMARDs (tsDMARDs) |
  • | * Anti-TNF Biologics (e.g., Adalimumab, Etanercept, Infliximab, Golimumab, Certolizumab): |
  • | - Pre-Treatment Screening MANDATE: Tuberculin Skin Test (TST) or QuantiFERON-TB Gold AND |
  • | Hepatitis B Serology (HBsAg, anti-HBc) to rule out latent infection reactivation. |
  • | - Black Box Warnings / Contraindications: Active severe infection, Demyelinating disease |
  • | (Multiple Sclerosis), NYHA Class III / IV Heart Failure (worsens congestive heart failure!). |
  • | * Non-TNF Biologics: |
  • | - Rituximab (Anti-CD20 B-cell depleter; screen for Hepatitis B reactivation / PML). |
  • | - Abatacept (T-cell co-stimulation modulator / CTLA-4-Ig). |
  • | - Tocilizumab / Sarilumab (IL-6 receptor antagonists; monitor LFTs, lipids, diverticulitis). |
  • | * Targeted Synthetic DMARDs (JAK Inhibitors: Tofacitinib, Upadacitinib, Baricitinib): |
  • | - Oral small molecules; Black Box Warnings for Major Adverse Cardiovascular Events (MACE), |
  • | deep vein thrombosis / pulmonary embolism (VTE), malignancies, and serious infections. |
  • | | |
  • | v (Bridge therapy only) |
  • | GLUCOCORTICOID BRIDGING |
  • | - Low-dose oral Prednisone (<= 10 mg/day) used strictly as short-term bridge therapy while |
  • | awaiting csDMARD onset of clinical efficacy (which requires 6 to 12 weeks). Taper promptly. |
  • +---------------------------------------------------------------------------------------------------+
  • 2. Systemic Lupus Erythematosus (SLE)
  • Pathophysiology & Diagnostic Criteria

SLE is a prototypical systemic autoimmune disease characterized by polyclonal B-cell hyperreactivity, defective clearance of apoptotic nuclear debris, production of antinuclear autoantibodies, and widespread tissue damage mediated by Type III (immune complex deposition) and Type II (autoantibody-mediated cytotoxicity) hypersensitivity reactions. +---------------------------------------------------------------------------------------------------+

  • | 2019 EULAR / ACR CRITERIA & THE "SOAP BRAIN MD" FRAMEWORK |
  • | |
  • | ENTRY CRITERION: Antinuclear Antibodies (ANA) titer >= 1:80 on HEp-2 cells (Mandatory!) |
  • | |
  • | * S - SEROSITIS (Pleuritis, Pericarditis / Pericardial effusion) |
  • | * O - ORAL ULCERS (Painless oral or nasopharyngeal ulcerations, especially on hard palate) |
  • | * A - ARTHRITIS (Non-erosive, inflammatory polyarthritis involving >= 2 peripheral joints) |
  • | * P - PHOTOSENSITIVITY (Skin rash in unusual reaction to sunlight) |
  • | * B - BLOOD CYTOPENIAS (Autoimmune hemolytic anemia, Leukopenia <4,000, Lymphopenia <1,000, |
  • | Thrombocytopenia <100,000/mcL in absence of other causes) |
  • | * R - RENAL DISORDER (Persistent proteinuria >0.5 g/24h or active cellular RBC casts) |
  • | * A - ANA POSITIVITY (Present in >99% of patients; high sensitivity, low specificity) |
  • | * I - IMMUNOLOGIC MARKERS (Anti-dsDNA, Anti-Smith [Anti-Sm], Antiphospholipid Antibodies) |
  • | * N - NEUROLOGIC DISORDERS (Seizures, Psychosis, Acute confusional state, Mononeuritis) |
  • | * M - MALAR (BUTTERFLY) RASH (Fixed erythema over malar eminences, SPARING NASOLABIAL FOLDS) |
  • | * D - DISCOID RASH (Erythematous raised patches with keratotic scaling, causing atrophic scars) |
  • +---------------------------------------------------------------------------------------------------+
  • Serologic Autoantibody Profile in SLE

Serologic Test Sensitivity Specificity Clinical Utility & Pearls

Antinuclear Antibody (ANA) > 99 % >99\% > 99% Low (~60%) Best initial screening test . High negative predictive value; if ANA is negative, SLE is virtually excluded.

Anti-dsDNA (Double-stranded DNA) ~60–70% > 95 % >95\% > 95% Highly specific. Titers fluctuate directly with disease activity ; elevated titers correlate with active Lupus Nephritis .

Anti-Smith (Anti-Sm) ~25–30% > 99 % >99\% > 99% Most specific autoantibody for SLE. Does NOT fluctuate with disease activity.

Anti-Ro (SSA) / Anti-La (SSB) ~30–40% Moderate Associated with subacute cutaneous lupus, secondary Sjögren syndrome, and Neonatal Lupus / Congenital Heart Block in offspring.

Complement (C3 and C4) Variable Variable Decreased / consumed (low C3/C4) during acute immune-complex mediated disease flares and active nephritis.

Antiphospholipid Antibodies ~30–40% Moderate Lupus Anticoagulant, Anticardiolipin IgG/IgM, Anti- β 2 \beta_2 β 2 ​ -glycoprotein I. Triggers arterial/venous thrombosis and recurrent pregnancy loss. Paradoxically causes prolonged PTT in vitro!

Drug-Induced Lupus Erythematosus (DILE)

Common Culprit Medications: Hydralazine , Procainamide , Isoniazid (INH) , Minocycline , Quinidine, and anti-TNF biologics.

Diagnostic Serologic Hallmark: Anti-Histone Antibodies are positive in > 95 % >95\% > 95% of cases .

Clinical Distinction from Idiopathic SLE: DILE characteristically SPARES the kidneys and central nervous system , Anti-dsDNA and Anti-Sm are typically negative, and complement levels are normal. Symptoms spontaneously resolve within weeks to months following discontinuation of the culprit drug.

Guideline-Directed SLE Management

Hydroxychloroquine (HCQ / Plaquenil): Strongly recommended as universal foundational therapy for ALL patients with SLE regardless of disease severity. HCQ reduces flare rates, prevents organ damage accrual, decreases thrombotic events, and reduces overall mortality. Dosed ≤ 5 mg/kg actual body weight/day \le 5\text{ mg/kg actual body weight/day} ≤ 5 mg/kg actual body weight/day to minimize retinal toxicity. Mandatory baseline and annual dilated ophthalmologic examinations after 5 years of therapy to screen for irreversible bull's-eye retinopathy.

Systemic Corticosteroids: Used for acute disease flares; high-dose pulse IV Methylprednisolone ( 1 , 000 mg/day x 3 days 1,000\text{ mg/day x 3 days} 1 , 000 mg/day x 3 days ) for organ-threatening complications (e.g., diffuse proliferative lupus nephritis, acute neuropsychiatric lupus).

Immunosuppressive Agents for Lupus Nephritis: Mycophenolate Mofetil (MMF) or IV Cyclophosphamide followed by maintenance MMF or Azathioprine; Belimumab (B-lymphocyte stimulator inhibitor) or Voclosporin as add-on therapy.

3. Polymyalgia Rheumatica (PMR) & Giant Cell Arteritis (GCA)

Polymyalgia Rheumatica and Giant Cell Arteritis represent distinct clinical manifestations along the same inflammatory disease continuum in older adults ( 15 – 20 % 15\text{--}20\% 15 – 20% of PMR patients develop GCA; up to 50 % 50\% 50% of GCA patients exhibit PMR features). +---------------------------------------------------------------------------------------------------+

  • | PMR vs. GCA DIAGNOSTIC & CLINICAL COMPARISON |
  • | |
  • | CLINICAL FEATURE POLYMYALGIA RHEUMATICA (PMR) GIANT CELL ARTERITIS (GCA) |
  • | --------------------------------------------------------------------------------------------- |
  • | Target Population Age >= 50 years (Mean age 73) Age >= 50 years (Mean age 75) |
  • | Anatomical Localization Synovial / Bursal structures of Medium & large elastic arteries |
  • | proximal shoulder & pelvic girdles (Temporal, ophthalmic, aorta) |
  • | Hallmark Symptoms Bilateral aching & severe morning New-onset unilateral headache, |
  • | stiffness in neck, shoulders, hips; jaw claudication, scalp |
  • | difficulty rising from chair. tenderness, amaurosis fugax. |
  • | Physical Examination Active ROM limited by pain; Tender, nodular, pulseless |
  • | muscle strength is NORMAL. temporal artery; visual defect. |
  • | Erythrocyte Sed. Rate (ESR) Markedly Elevated (often > 50-100) Markedly Elevated (often > 100) |
  • | Creatine Kinase (CK) NORMAL (Rules out myositis/statin) NORMAL |
  • | Gold Standard Diagnostic Clinical diagnosis + rapid TEMPORAL ARTERY BIOPSY (TAB) |
  • | response to low-dose steroids. (>= 1-2 cm specimen, skip lesions)|
  • | First-Line Therapy Low-Dose Oral Prednisone HIGH-DOSE SYSTEMIC STEROIDS |
  • | (15 - 20 mg daily). (Prednisone 40-60 mg PO daily; |
  • | IV Methylprednisolone 1 g daily |
  • | if visual loss threatened!). |
  • | Primary Complication Chronic steroid adverse effects IRREVERSIBLE BLINDNESS (AION) |
  • +---------------------------------------------------------------------------------------------------+
  • Polymyalgia Rheumatica (PMR)

Clinical Presentation: Rapid or subacute onset of bilateral, symmetric aching pain and debilitating morning stiffness ( > 45 – 60 minutes >45\text{--}60\text{ minutes} > 45 – 60 minutes ) involving the proximal shoulder girdle (neck, deltoids), pelvic girdle (hips, buttocks), and upper thighs . Patients describe profound difficulty raising their arms to comb hair, reaching into high cabinets, putting on a coat, or standing up from a low seated position.

Diagnostic Confirmation: Markedly elevated ESR ( > 50 mm/hr >50\text{ mm/hr} > 50 mm/hr ) and CRP; normal muscle enzymes ( Creatine Kinase is strictly normal , ruling out polymyositis, dermatomyositis, and statin-induced myopathy); negative RF and anti-CCP. Dramatic clinical improvement within 24 to 72 hours of initiating low-dose oral prednisone (15–20 mg/day) confirms the presumptive diagnosis. Steroids are gradually tapered over 1 to 2 years.

Giant Cell Arteritis (GCA / Temporal Arteritis) — Medical Emergency

Pathophysiology: Granulomatous vasculitis involving the medium and large arteries branching from the carotid system, especially the superficial temporal, ophthalmic, and posterior ciliary arteries.

Clinical Red Flags:

New-onset headache: Typically localized to the temporal or occipital region.

Jaw Claudication: Agonizing fatigue/cramping of the masseter muscles during mastication (pathognomonic sign of vascular ischemia!).

Scalp Tenderness: Pain elicited by brushing hair or resting head on a pillow.

Temporal Artery Changes: Palpable, tender, thickened, nodular, or pulseless temporal artery.

Visual Symptoms: Transient monocular vision loss ( Amaurosis Fugax ), diplopia, or sudden, painless, irreversible blindness secondary to Anterior Ischemic Optic Neuropathy (AION) .

Urgent Action Protocol: +---------------------------------------------------------------------------------------------------+

  • | EMERGENT GCA CLINICAL MANAGEMENT PROTOCOL |
  • | |
  • | 1. HIGH CLINICAL SUSPICION (New headache + Jaw claudication + ESR > 50-100 mm/hr) |
  • | | |
  • | v |
  • | 2. IMMEDIATELY INITIATE HIGH-DOSE SYSTEMIC CORTICOSTEROIDS |
  • | - Uncomplicated GCA (No visual loss): PREDNISONE 40 - 60 mg PO DAILY. |
  • | - Ocular Involvement (Amaurosis fugax, acute vision loss): IV METHYLPREDNISOLONE |
  • | 1,000 mg IV DAILY for 3 days, followed by high-dose oral prednisone. |
  • | * CRITICAL BOARD RULE: NEVER DELAY STEROID THERAPY TO AWAIT TEMPORAL ARTERY BIOPSY! |
  • | | |
  • | v |
  • | 3. SCHEDULE TEMPORAL ARTERY BIOPSY (TAB) OR VASCULAR ULTRASOUND |
  • | - Obtain a long segment biopsy (>= 1.5-2.0 cm) to avoid missing segmental "skip lesions." |
  • | - Biopsy remains histopathologically positive for up to 1 to 2 weeks after steroid initiation.|
  • | - Color Doppler Ultrasound may show the "halo sign" (hypoechoic vessel wall edema). |
  • +---------------------------------------------------------------------------------------------------+

4. Board-Yield Summary & Clinical Pearls +---------------------------------------------------------------------------------------------------+

  • | ANCC AGPCNP CLINICAL EXAM PEARLS |
  • | |
  • | - Rheumatoid Arthritis: Morning stiffness >60 minutes, symmetric, targets MCP/PIP/wrist, |
  • | SPARES DIP! Anti-CCP is >95% specific. Start Methotrexate early + co-prescribe Folic Acid. |
  • | |
  • | - Before starting TNF-inhibitors (Adalimumab, Etanercept): MANDATORY screening for Latent TB |
  • | (QuantiFERON) and Hepatitis B. Absolutely contraindicated in severe CHF (NYHA III/IV) and MS! |
  • | |
  • | - SLE Serology: ANA = Best initial screen (>99% sensitive). Anti-dsDNA = Correlates with |
  • | Lupus Nephritis flares and consumes complement (low C3/C4). Anti-Smith = Most specific. |
  • | Drug-induced lupus (Hydralazine, INH, Procainamide) = Anti-Histone positive. |
  • | |
  • | - Polymyalgia Rheumatica vs. Polymyositis: PMR has bilateral shoulder/pelvic morning stiffness, |
  • | ESR >50, but NORMAL Creatine Kinase (CK) and normal strength. Responds instantly to low-dose |
  • | prednisone (15-20 mg). Polymyositis has TRUE proximal muscle weakness and elevated CK! |
  • | |
  • | - Giant Cell Arteritis: Elderly patient with temporal headache, jaw claudication, and visual |
  • | changes. DO NOT wait for biopsy—start high-dose steroids (Prednisone 60 mg) IMMEDIATELY to |
  • | prevent irreversible ischemic blindness! |
  • +---------------------------------------------------------------------------------------------------+